{
  "docId": "019de074-05b7-71fd-bc3c-27f1b7be8924",
  "docSlug": "c3cb552ef3a6b077a714c97117e1fe86",
  "documentTitle": "Mink Therapeutics | Investor Day Presentation Deck | 92 slides",
  "authorId": "mink-therapeutics",
  "authorName": "MiNK Therapeutics",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 92,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "agenda",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-05b7-71fd-bc3c-27f1b7be8924/19",
  "deckHref": "/decks/019de074-05b7-71fd-bc3c-27f1b7be8924",
  "deckJsonHref": "/decks/019de074-05b7-71fd-bc3c-27f1b7be8924.json",
  "deckAnchorHref": "/decks/019de074-05b7-71fd-bc3c-27f1b7be8924#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.069,
        "w": 0.904,
        "x": 0.048,
        "y": 0.778
      },
      "kind": "list",
      "text": "Allo-iNKTs (agenT-797) reinvigorates partially exhausted T cells and improves effector functions within the tumor microenvironment; critical mechanisms in rescuing PD-1 refractory tumors.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "02f3d86e-dcea-41a2-a4ca-00ab9c6cc415",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.103,
        "w": 0.904,
        "x": 0.048,
        "y": 0.481
      },
      "kind": "list",
      "text": "MiNK’s FAP-CAR-iNKT, MiNK-215, demonstrates robust efficacy in NSCLC models, promoting curative responses, eliminating tumor burden in the lungs, and enhancing tumor specific CD8+ T cell infiltration through tumor stroma.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5c44db7a-5cc4-4c5d-b2b3-b402264b55d3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.069,
        "w": 0.904,
        "x": 0.048,
        "y": 0.352
      },
      "kind": "list",
      "text": "agenT-797 shows 70% survival in severe viral ARDS compared to reference controls (~10%); potential for a variant agnostic approach to severe infections and pulmonary diseases.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "675c30cc-50b6-41dc-b6c1-0bcd4831e1dc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.138,
        "w": 0.904,
        "x": 0.048,
        "y": 0.184
      },
      "kind": "list",
      "text": "Allogeneic unmodified iNKTs (agenT-797) show reductions in target and non-target lesions or disease stabilization in patients with solid tumor cancers when administered alone [27%] and in combination with pembrolizumab (KEYTRUDA®) or nivolumab (OPDIVO®) [66%].",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "73c8f0d6-4e5a-4005-9383-daaba1ec6c91",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.069,
        "w": 0.904,
        "x": 0.048,
        "y": 0.649
      },
      "kind": "list",
      "text": "MiNK-413 is a differentiated allogeneic IL-15-armored-BCMA-CAR-iNKT, a next generation approach to overcome the limitations of current autologous cell therapies.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "acee8d09-8c82-4f30-a3f1-08508d473858",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.108,
        "w": 0.415,
        "x": 0.048,
        "y": 0.048
      },
      "kind": "title",
      "text": "Today we will hear...",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "35ec9741-dfe5-42c3-8f77-eb8e3dfb8708",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 22,
      "from": 18,
      "beatId": "712f2bca-7294-4694-b198-ee95567c1d0b",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Proposed Solution",
      "beatSlug": null,
      "evidence": "The presentation introduces iNKT cells as a potential solution",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 22,
      "from": 17,
      "name": "Logic Chain",
      "slug": "01-logic-chain",
      "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis",
      "matchId": "564e86af-6c91-4448-9e43-c23c0dddd4ef",
      "evidence": "The presentation builds a logical argument for iNKT cells' potential",
      "position": 0,
      "objective": "Establishing the rationale for iNKT cells in cancer treatment",
      "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)",
      "confidence": 0.7,
      "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}